- Sections
- A - Nécessités courantes de la vie
- A61K - Préparations à usage médical, dentaire ou pour la toilette
- A61K 39/205 - Rabdoviridae, p.ex. virus de la rage
Détention brevets de la classe A61K 39/205
Brevets de cette classe: 269
Historique des publications depuis 10 ans
|
12
|
16
|
16
|
16
|
19
|
15
|
19
|
19
|
16
|
0
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Thomas Jefferson University | 526 |
13 |
| Curevac SE | 249 |
13 |
| The University of Western Ontario | 320 |
9 |
| Glaxosmithkline Biologicals S.A. | 1696 |
6 |
| Intervet International B.V. | 1283 |
6 |
| University of Massachusetts | 2191 |
6 |
| Wyeth LLC | 671 |
5 |
| Children's Hospital of Eastern Ontario Research Institute Inc. | 30 |
5 |
| The Government of The United States of America AS represented by The Secretary of The Department of Health and Human Services, Centers for Disease Control and Prevention | 52 |
5 |
| Intervet Inc. | 872 |
5 |
| University of Georgia Research Foundation, Inc. | 1004 |
5 |
| Variation Biotechnologies, Inc. | 75 |
5 |
| Yale University | 2289 |
5 |
| CureVac AG | 149 |
4 |
| Merial Limited | 133 |
4 |
| Novavax, Inc. | 155 |
4 |
| Sanofi Pasteur SA | 74 |
4 |
| Takeda Vaccines, Inc. | 211 |
4 |
| Bioapplications Inc. | 59 |
3 |
| Centers for Disease Control and Prevention | 21 |
3 |
| Autres propriétaires | 155 |